Brought to you by 
Solvay agrees to acquire Fournier
Mar 2005
Executive Summary
To strengthen its cardiology business and research pipeline, Solvay has signed a memorandum of understanding to buy Fournier Pharma for €1.3bn ($2.1bn) in cash. Both have portfolios of drugs to treat cardiovascular, gastroenterological, psychiatric, and gynecological conditions.
Deal Industry
- Pharmaceuticals
Deal Status
- Preliminary
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Solvay agrees to acquire Fournier
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice